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Executive Summary 
 
 The Commission to Study Bulk Purchasing of Prescription Drugs and Medical Supplies, 
created by Resolve 1999, chapter 75, was established to address the increasing costs of 
prescription drugs and the lack of affordable access to insurance c verage for prescription drugs.  
The 12-member Commission met four times in October and November 1999, and explored 
information and proposals concerning prescription drug costs and expenditures.  The Commission 
unanimously reached the following recommendations. 
 
1.  The Commission recommends that the State should not at this time  pursue bulk 
purchasing of prescription drugs as a separate program.   
  
2.  The Commission recommends that the State expand educational outreach to inform 
Maine citizens about the many State, Federal and private programs available to reduce 
prescription costs.   
  
3.  The Commission recommends that the State investigate the feasibility of joining with 
other states, especially in local or regional affiliations, to lower prescription drug costs to 
consumers. 
  
4.  Recognizing that the Legislature and the Department of Human Services anticipate that 
the Maine Residents Low-Cost Drug Program will reduce prescription drug costs to 
consumers, the Commission recommends that the State move forward as rapidly s 
possible with the rule-making and legislative process to implement the program. 
  
5.  The Commission recommends that the availability of access to reduced-cos  p scription 
drugs through the federal Office of Drug Pricing be explored more thoroughly to 
determine whether prescription drugs at a lower price can be made more available to 
programs providing services to Maine residents.   
  
6.  The Commission recommends that the State encourage a public-private partnership to 
generate, maintain and distribute a simple and coordinated therapeutic and pricing 
guideline for physicians and other prescribers. 
  
7.  The Commission recommends that the State encourage public-p ivate partnerships for 
expanded purchasing volume, thereby increasing consumer’s opportunity to purchase 
prescription drugs at lower prices. 
  
8.  The Commission recommends that the Department of Human Services continue to pursue 
the Medicaid waiver with the Health Care Financing Administration. 
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I Introduction 
 
 A.  Inception of the study 
 
 During the First Regular Session of the 119th Legislature, the Joint Standing Committee 
on Health and Human Services was asked to find ways to address the increasing costs of 
prescription drugs and the lack of ffordable access to insurance coverage for prescription drugs.  
Many legislative proposals made their way to the Committee.  Several bills advocated 
modifications in the Elderly Low-Cost Drug Program.  Other bills proposed establishing a 
purchasing consortium to make prescription drugs available at lower cost to low-income and 
elderly residents of the State.  The Committee supported changes to the Elderly Low-Cost Drug 
Program (enacted as part of the Budget Bill, PL 1999, c. 401, Part KKK, as amended by PL 
1999, c. 531, Part F), and created the Maine Resident Low-Cost Drug Program (PL 1999, c. 431, 
see Appendix D).  In addition,  the Committee recommended and the Legislature approved the 
creation of the Commission to Study Bulk Purchasing of Prescription Drugs and Medical 
Supplies, referred to in this report as “the Commission,” initially proposed in LD 206 and finally 
passed as Resolve 1999, chapter 75. 
 
 
 B.  Study charge 
 
 The Health and Human Services Committee determined that a comprehensive study of 
bulk purchasing of prescription drugs and medical supplies was needed to determine whether bulk 
purchasing could be used to provide Maine residents access to affordable prescription drugs and 
medical supplies.  The Commission was directed to examine the need for a bulk purchasing 
mechanism, and to determine if there would be financial benefits and potential savings to private 
citizens, insurance carriers, self-insured employee health benefit plans and publicly funded health 
coverage.  The charge also required the Commission to evaluate the potential impact of bulk 
purchasing on the State's economy and on pharmacies, hospitals and other health care facilities 
within the State.  Resolve 1999, chapter 75, included as Appendix A, sets out the complete 
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charge to the Commission. 
 
 Early in its deliberations, the Commission determined that a broader focus was necessary, 
and that more ideas need to be explored in order to improve access to prescription drugs.  It 
therefore interpreted its charge as a starting point, and used its meetings to examine additional 
approaches.   The Commission also determined that its top priority was making prescription drugs 
more affordable, and therefore did not address durable medical equipment and medical supplies. 
 
 
 C.  Study process 
 
 The Commission to Study Bulk Purchasing of Prescription Drugs and Medical Supplies 
consisted of 12 members, appointed by the Senate President, the Speaker of the House of 
Representatives and the Governor.  In addition to six legislators representing both major political 
parties, the membership included the following persons: a member of a professional organization 
representing pharmaceutical manufacturers; a member of a statewide organization representing 
health care carriers regulated under Titles 24 and 24-A of the Maine Revised Statutes; a member 
from a statewide organization representing hospitals; a member of a statewide organization 
representing pharmacies; a member from a statewide organization representing pharmaceutical 
wholesalers; and the Director of he Bureau of Medical Services within the Department of Human 
Services, or the Director’s designee.  A list of the members is included as Appendix B. 
 
 The Commission met four times, as authorized by the enabling legislation, in October and 
November 1999 at the State House in Augusta.  Interested parties attended the meetings, 
contributed ideas and participated in the Commission’s discussion.  The Commission members 
themselves brought an exceptional combination of personal and professional knowledge and 
experience, which allowed the discussion to start at a very high level and to progress from there. 
 
 The Commission examined the benefits and costs of the State’s entering into the 
prescription drug market as a bulk purchaser.  The discussion covered the following elements that 
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the State would have to include in its bulk purchasing distribution system:  The ability to deliver 
prescription drugs to pharmacies throughout the state within hours of ordering; the ability to 
stock a large number of different drugs, including branded and generic; the storage requirements 
for some drugs, such as refrigeration; a large investment in technology; and the ability to track 
drugs throughout the distribution system to handle recalls or other problems.  The existing 
distribution system contains all these elements; the State bulk purchasing program would have to 
duplicate each element.  Another significant cost identified early in the discussion is the 
detrimental effect that such action may have on Maine businesses that are curr ntly part of the 
wholesale and retail prescription drug business.  For these reasons, the Commission agreed that it 
would also look beyond bulk purchasing to identify any other actions that would help the 
Legislature address the underlying problem of high prescription drug costs for those without any 
prescription drug coverage.  The members and interested parties made additional suggestions.  
The Commission’s recommendations are included in Part III of this report.
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II Background 
 
 A.  Prescription drugs  
 
 Prescription drugs are an integral component of today’s health care system.  Medications 
can be more cost-effective and less invasive than other forms of treatment, and  they play 
important roles in the entire range of treatment, from saving lives to maintaining productive lives 
and lifestyles.  Use of medications often results in lower overall health care costs for conditions 
such as asthma, AIDS, diabetes, heart disease, osteoporosis and stroke1.  T king prescription 
drugs does not eliminate visits to the health care provider – physicians and other prescribers still 
must ensure that the dosage is correct, determine whether the medication is having the desired 
effect and monitor the patient’s condition and progress – but the resulting improvements they 
produce are significant. 
 
 Health care spending has been on the increase, and many studies have been undertaken to 
identify trends and factors.  Just as prescription drugs are an important component in providing 
health care, they play an important role i  costs, too.  A study published by the National Institute 
for Health Care Management Foundation reported that total national health expenditures 
experienced an average annual percentage growth of 5.5% from 1992 to 1997.  Prescription drug 
expenditures over the same period increased an average of 11.1% annually.  This difference 
resulted in prescription drugs becoming a larger factor in total national health expenditures, 
increasing from 5.6% in 1992 to 7.2% of expenditures in 19972. I Maine, Medicaid 
expenditures, after rebates, for outpatient prescription drugs increased by 9.5% from state fiscal 
year 1996-1997 to 1997-1998, and by 20.3% from 1997-1998 to 1998-19993.  The 
pharmaceutical industry figures paint a less stark picture:  The Pharmaceutical Reseacrh and 
                                         
1 PhRMA, Backgrounder: The Myth of “Rising Drug Prices” Exposed, January 14, 1999, page 1. 
 
2 National Institute for Health Care Management, Factors Affecting the Growth of Prescription Drug Expenditures, 
Barents Group LLC, July 1999, page 1. 
 
3 Spreadsheet from Christopher Nolan, Department of Human Services, November 29, 1999, included as Appendix 
C. 
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Manufacturers of America (PhRMA) reports that the percentage of Gross Domestic Product 
(GDP) spent on prescription drugs has stayed at about one-h lf of one percent for the past 30 
years, while the portion of GDP devoted to health care has increased from 7.4 % in 1970 to an 
estimated 14.4% in 19964. 
 
 A change in regulatory restrictions on print and television advertising has resulted in many 
new direct-to-consumer (DTC) advertising campaigns.  About $1.3 billion was spent on DTC 
advertising in 19985.  The ten drugs most heavily advertised to consumers in 1998 accounted for 
$9.3 billion or about 22 percent of the total increase in drug spending between 1993 and 1998.   
 
 A portion of the increased expenditures on pharmaceuticals is related to ri ing drug prices.  
Several studies have pointed out large price increases for individual items6. One study attributes 
64% of the increased spending to higher per prescription prices7; an the  study calculated that the 
prices for the 50 prescription drugs most frequently used by the elderly rose more than four times 
the rate of inflation during calendar year 19988.  Maine Medicaid prescription drug expenditures 
per prescription increased 22.8% from state fiscal year 1996-1997 to 1 97-19989.  An additional 
reason that the average price per prescription has gone up so dramatically is the introduction of 
expensive new drugs that replace lower-cost existing medications.  On average, the new drugs 
cost more than twice as much as older drugs10. 
                                         
4 PhRMA, Backgrounder: Prescription Drug Prices and Profits, page 4. 
 
5 National Institute for Health Care Management, Factors Affecting the Growth of Prescription Drug Expenditures, 
Barents Group LLC, July 1999, page 12. 
 
6 Families USA, Hard to Swallow, Rising Drug Price’s for America’s Seniors, November 1999; National Institute 
for Health Care Management, Factors Affecting the Growth of Prescription Drug Expenditures, Barents Group 
LLC, July 1999; Access and Affordability Monitoring Project, Boston University School of Public Health, 
Affordable Medications for Americans, Al  Sager, Ph.D., Deborah Socolar, M.P.H., July 1999. 
 
7 National Institute for Health Care Management, Factors Affecting the Growth of Prescription Drug Expenditures, 
Barents Group LLC, July 1999, page 15. 
 
8 Families USA, Hard to Swallow, Rising Drug Price’s for America’s Seniors, November 1999, page 2. 
 
9 Spreadsheet from Christopher Nolan, Department of Human Services, November 29, 1999, included as Appendix 
C. 
 
10 National Institute for Health Care Management, Factors Affecting the Growth of Prescription Drug 
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 Rising drug expenditures are also attributable to greater drug utilization nationwide.  The 
number of prescriptions filled increased from 1.9 billion in 1993 to 2.5 billion in 1998, a jump of 
600 million prescriptions11.  According to IMS Health, an organization that tracks pharmaceutical 
sales at the retail level, a large portion of the increase in expenditures for prescription drugs in 
1998 is accounted for by the increased use of drugs, as well as the fact that doctors are more 
frequently prescribing newer, innovative and sometimes more costly medicines.  For some leading 
therapeutic categories, the total utilization rate more than doubled between 1993 and 1998.  For 
example, the number of prescriptions filled for oral antihistamines increased by 500% to 41 
million prescript ons; the number filled for cholesterol- ow ing medications increased by 162% to 
68 million prescriptions, and for antidepressants, the number increased by 111% to 120 million.  
Also increasing is the number of prescriptions written and filled per person; therapies often 
include more than one medication to treat a particular illness or condition.  Maine Medicaid 
outpatient prescription drug figures show a per person increase in the number of prescriptions of 
5.6% from state fiscal year 1996-19 7 to 1998-199912. 
 
In addition, more drugs are being introduced to treat conditions that formerly were not 
treatable by medication.  The increase in use of drugs rather than surgery or to prevent heart 
attacks and strokes, for example, results in greater expenditures for drugs, but greatly lowers or 
eliminates expenditures in other categories of health care.  A recent study showed that a new 
medicine to prevent osteoporosis costs just $3,000 over 15 years – instead of $41,000 for hip 
replacement surgery13.  New therapies are changing the quality of life, reducing the length of 
hospital stays and decreasing other, often more expensive and more invasive, components of 
medical care. 
                                                                                                                              
Expenditures, Barents Group LLC, July 1999, page 18.
 
11 National Institute for Health Care Management, Factors Affecting the Growth of Prescription Drug 
Expenditures, Barents Group LLC, July 1999, page 21. 
 
12 Spreadsheet from Christopher Nolan, Department of Human Services, November 29, 1999, included as 
Appendix C. 
 
13 PhRMA, Backgrounder: Prescription Drug Prices and Profits, page 4. 
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 B.  Methods of paying for prescription drugs available in Maine 
 
 There are three ways Maine residents obtain their prescription drugs.  Many have 
prescription drug coverage as part of a comprehensive health benefit program.  These consist of 
both private and public programs, including private insurance programs, Medicaid and Cub Care, 
the state children’s health care program established under Title XXI of the federal Social Security 
Act.  Second, some receive benefits under stand-alone state drug benefit programs.  The Elderly 
Low-Cost Drug Program is one such program, under which the participant receives drug benefits, 
but no other health benefits.  Despite the availability of these programs, many consumers have no 
prescription drug insurance and do not qualify for any of the federal or state public programs that 
provide prescription drug benefits; they pay cash for their medications, or they do without.  
Although the Department of Human Services is in the process of determining a more accurate 
figure for who is not covered by any form of prescription drug program, there are estimates that 
as many as 20- 5% of all Mainers fall into this category.  Many of these consumers are elderly, on 
fixed incomes, or both, and, because no one negotiates price discounts for them, they usually pay 
the highest prices for prescription drugs.  Prescription benefit managers negotiate with 
manufacturers for better prices for their insureds; the federal government obtains lower prices for 
huge purchasers such as the Department of Defense and the Veterans Administration; the federal 
government also mandates manufacturers’ rebates for the Medicaid program through a statutory 
formula; the federal Office of Drug Pricing negotiates reduced prices for certain federal health 
care grant recipients.  Some studies indicate that as the larger purchasers negotiate lower and 
lower prices, the costs of providing those lower prices are shifted to the cash-paying consumers, 
who usually end up paying the highest prices of all. 
 
 Perhaps the hardest hit are the elderly.  Per capita, persons over 62 use more prescription 
drugs than any other segment of the population.  They rely on medication to keep them out of  
hospitals and nursing homes, help them maintain their health and continue to be participating, 
productive members of the community.  Many people do not have prescription drug benefits once 
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they retire, ironically the time in their lives when they could benefit most from the coverage.  
Although it is at the top of the list for Medicare reform, there is currently no prescription drug 
benefit for outpatients under Medicare.  Medicare recipients who want prescription drug coverage 
have the option of purchasing on the private market different “Medi-gap” polici s which may be 
cost prohibitive.  It has been reported that, for some, although there is currently limited 
information about the number of such people in Maine, the cost of their prescription medications 
is so high that they must choose between paying their rent and filling their prescription.  
According to testimony presented at a joint public hearing of the Joint Standing Committees on 
Health and Human Services and Taxation on March 3, 1999, some elderly couples often have to 
choose whose prescription will be filled, because their limited income will not pay for all the 
medications they both need.
 
 Some uninsureds have taken the step of traveling to where lower prescription drug prices 
are paid by the uninsured consumer.  On more than one occasion, senior citizens in Maine have 
boarded buses for Quebec, where prices for prescription drugs that are on the Quebec formulary 
are as low as two-thirds the cost in the United States.  One such trip was featured on 60 Min tes 
in October 1999. 
 
 Individual research-based pharmaceutical manufacturers have developed prescription drug 
patient assistance programs.  Each manufacturer designs andadmi i ters its own program.  
Through these programs manufacturers provide prescription medicines free of charge to 
physicians whose patients might not otherwise have access to necessary medicines.  The duration 
of benefits varies by drug and manufacturer.  PhRMA publishes a directory of these programs, 
and includes instructions on how to access the benefits.  In 1998, PhRMA member company 
programs provided 2.8 million prescriptions for 1.5 million patients in the United States.  The 
wholesale value of those drugs totaled $500 million.  A more coordinated approach to these 
programs, recognizing anti-trust restrictions, could greatly benefit consumers; a single website on 
the Internet maintained by an independent entity may be extremely useful. 
 
 Maine law authorizes the voluntary establishment of private purchasing alliances.  An 
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alliance is a nonprofit corporation licensed under the Insurance Code to provide health insurance 
to its members through multiple unaffiliated carriers.  Alliances are authorized to set thei  own 
standards for membership in the alliance.  These entities are designed to provide additional 
options for the purchase of insurance by small employers.  Although the law became effective in 
July 1996 and the rules governing alliances were finally adopted in March 1997, there are no 
licensed purchasing alliances in the State.  Employers and others may want to explore the 
establishment of private purchasing alliances to provide prescription drug coverage for their 
employees. 
 
 
 C.  Maine prescription drug programs 
 
 Maine has established a number of programs under which participants receive prescription 
medication for no charge, for a co-pay or at a reduced price. 
 
  1.  Medicaid.  (22 MRSA §3174-G, subsection 1)  In Maine, the Medicaid 
program is the largest payor for prescription medication, as well as for hospitalization and care by 
physicians and other providers.  To qualify for Medicaid, a person must meet income criteria and 
be a member of a category covered by Medicaid, referred to as being “categorically eligible.”  In 
Maine Medicaid categories include: 
a.  Children up to age 12 months and pregnant women - both at family income levels up to 
185% of the federal poverty level (fpl) ; 
b.  The elderly and the disabled - both at family incomes up to 100% fpl;  
c.  Children ages one through 18 - at family incomes up to 150% fpl; and   
d.  Families qualified to receive benefits under the Temporary Assistance to Needy 
Families (TANF) program under 22 MRSA chapter 1053-B. 
 
The income limits have some flexibility for people who have high medical expenses, 
known as “spend down” eligibility.  There are no co-pays for children.  Adults may have a 
variable co-pay of up to $3 on some services.  Co-pays are very limited by the federal 
COMMISSION TO STUDY BULK PURCHASING OF PRESCRIPTION DRUGS AND MEDICAL SUPPLIES 
10 
government. 
 
  2. Cub Care.  (22 MRSA §3174-T)  The Cub Care program provides health 
coverage for children ages one year through 19, at family incomes up to 200% of the federal 
poverty level.  The income limit was increased from 185% on October 1, 1999 under the 
Commissioner’s powers to increase or decrease the income limit to maximize coverage within the 
funding limits of the program under 22 MRSA §3174-T, subsection 2, paragraph A.  It is 
anticipated that the increased coverage will be provided within the original Cub Care state and 
federal budget amounts during state fiscal year 1999-2000.  
 
Beginning July 1, 2000 the income limit is raised to 200% of the federal poverty level (fpl) 
by statute, PL 1999, Chapter 401, Part QQ.  Additional funding of $466,796 is provided from the 
Fund for a Healthy Maine (the national tobacco settlement money) for the cost of benefits.  Also 
allocated from the Fund for a Healthy Maine during state fiscal year 2000-2001 is $ 9,587 for a 
staff person in the Department of Human Services (DHS) for Cub Care administration.  Matching 
federal funds were allocated for both accounts.   
 
Children age birth through age 12 months are covered under the Medicaid program, 
because persons eligible for Medicaid are required by federal law to be covered under that 
program.  This creates a bit of a gap between the pregnant women and children to age 12 months, 
with incomes to 185% fpl, who are on Medicaid and the Cub Care children at 200% fpl.  DHS is 
considering the challenge presented by this disparity. 
 
The Cub Care program provides full health care benefits, including prescription medicines 
and supplies, exactly the same as the Medicaid program.  There are no co-pays.  
 
Families are required to pay contributions for coverage (premiums), depending on family 
income, calculated at 5% of benefit cost for families at 150-160% fpl, 10% of benefit cost for 
families at 160-170% fpl, and 15% of benefit cost for families at 170-185% fpl.  There is a 
maximum (the base times 2) in each category of income.  The benefit cost is an average for the 
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program, currently around $1200 per year per child.  There is no statutory premium figure for 
children 185 to 200% fpl; DHS will presumably charge them the same as children with family 
incomes 170-185% fpl. 
 
  3.  Elderly Low-Cost Drug Program.  (22 MRSA 254, as amended by LD 617, 
PL 1999, chapter 401, Part KKK, as further amended by LD 2255, PL 1999, chapter 531, Part F)   
 
 a.  The basic component.  The basic component of the Elderly Low-Cost Drug Program 
(ELCDP) provides assistance with payment for prescription medicines for adults ages 62 and over 
and disabled adults for certain specified chronic medical conditions.  The conditions covered 
include cardiac and high blood pressure, diabetes, arthritis, anticoagulation, hyperlipidemia, 
osteoporosis, chronic obstructive pulmonary disease and asthma, incontinence, thyroid diseases, 
glaucoma, Parkinson’s disease, multiple sclerosis and amytrophic lateral sclerosis (Lou Gehrig’s 
disease). 
 
Beginning August 1, 1999, the existing ELCDP was revamped to increase the income 
level and designate it as the basic component of the ELCDP.  The income level for the ELCDP 
increased from roughly 131% of the federal poverty level to 185%.  Before August 1, 1999, the 
income level was determined by reference to the Maine Residents Property Tax Program (the 
“circuit breaker” program) and was not expressed as a percentage of the federal poverty level.  
Persons who pay more than 40% of their income for unreimbursed prescription drugs are eligible 
for the basic component up to an additional 25% of the applicable income levels.  The co-pay is 
$2 or 20%, whichever is greater.   
 
 b.  The supplemental component.  The “supplemental component of the program” came 
into effect August 1, 1999.  The supplemental component of the program covers all prescription 
drugs and medications provided under the Medicaid program with certain exceptions.  Under the 
supplemental component of the program participating manufacturers will discount their drug 
prices by the same amount as the Medicaid discount.   
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DHS will pay $2 toward the cost of the prescription.  The consumer will pay the 
remainder.  The effect of the DHS $2 co-pay and the Medicaid level discount will be a discount to 
the consumer that is estimated to be about 20% off current prices paid by those without drug 
coverage.   
 
No state funds were allocated or appropriated for the supplemental component of the 
program.  It is intended to be self-sufficient, operating on the discounts and $2 DHS co-pay. 
 
  4. Maine Resident Low-Cost Prescription Drug Program.  (22 MRSA §254-B, 
from LD 2082, Public Law 1999, chapter 431)  Beginning February 1, 2000, or as soon thereafter 
as possible, a new program is scheduled to take effect:  the Maine Resident Low-Cost 
Prescription Drug Program, MRLCPDP.  Under this program manufacturers who choose to 
participate voluntarily pay rebates to DHS.  DHS plans to set the voluntary rebates approximately 
the same amount as the Medicaid rebates (around 18-20% at present).   According to DHS, a 
manufacturer who chooses to participate must participate for all drugs sold in the state. 
 
When filling a prescription, the consumer picks whichever participating pharmacy he or 
she wishes and may perhaps have a choice of manufacturer.  The pharmacist discounts the 
prescription from the pharmacy’s normal price by the discount amount established by DHS 
(roughly the rebate amount).  Except for applying the mandatory discount to drugs provided by a 
participating manufacturer, the pharmacy is free to set its own prices, so the consumer’s price for 
a drug produced by a participating manufacturer may vary from pharmacy to pharmacy.   
 
If the drug purchased is one for which a discount has been applied, the pharmacy notifies 
DHS and DHS pays the discount amount to the pharmacy weekly or bi ly.  To qualify for 
MRLCPDP the consumer must be a Maine resident and have no 3rd party prescription drug 
coverage.  There is no enrollment procedure or identification card.  Eligibility is established by the 
pharmacist when the consumer fills the prescription. 
 
DHS is preparing rules that should address many of the concerns raised during the 
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hearings before passage of LD 2082 and reiterated to the Commission.  Those concerns include: 
· The method by which DHS will calculate the discount per drug without revealing the 
amount of the Medicaid rebate paid for that drug;
· The way or ways by which pharmacies will be expected to determine whether an 
individual is a Maine resident and has no prescription drug coverage; 
· How Maine residents will know which companies are participating in the program, and 
which drugs are produced by those companies; 
· How Maine residents will know that the discount is paid by the manufacturer, and 
does not come from the State; and 
· How DHS will implement the statutory requirement that the rules “promote the use of 
efficacious and lower-cost drugs.” 
 
MRLCPDP is self- unded by the voluntary rebates paid by participating manufacturers.  
There is no state appropriation to support this program.  There are allocations of $2,500,000 in 
state fiscal year 1999-2000 and $10,000,000 in 2000-20 1 from the rebate amounts paid in to 
DHS by the participating manufacturers. 
 
The MRLCPDP will take effect only after DHS completes the rule-making process, which 
includes a public hearing on the proposed rules.  Once the rules are provisionally adopted, they 
must be submitted to the Legislature for review and approval as “major substantive” rules.
 
  5.  Medicaid waiver drug program.  (22 MRSA §3174-G, subsection 1-A, from 
LD 617, Public Law 1999, chapter 401, Part KKK, as amended by LD 2255, Public Law 1999, 
chapter 531, Part F)  The statute directs DHS to apply for a Medicaid waiver to provide Medicaid 
prescription drug benefits as follows. 
· Qualified persons ages 62 and over and disabled persons ages 19 and over are eligible for 
benefits.  The family income limitation for both sets of persons is 185% fpl.  Coverage 
under the Medicaid waiver drug program is contingent upon sufficient funds being 
appropriated and allocated to cover costs.  If funding is insufficient, the income limit is to 
be decreased. 
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· The full range of drugs provided in the Medicaid program must be provided.   
· There is no asset limitation.   
· Co-payments are comparable to Medicaid co-payments.   
· Coverage is required to begin July 1, 2000 or as soon thereafter as possible. 
 
Funding is governed by 22 MRSA §3174-G, subsection 1-B and is to be provided by a 
combination of funds: 
a.  Funding appropriated to the Elderly Low-Cost Drug Program and any rebates paid 
under that program, 
b.  Funding of at least $5,000,000 in state fiscal year 2000-2001 from the Fund for a 
Healthy Maine, and 
c.  Allocated federal matching funds for state fiscal year 2000-2001 of $23,804,694. 
 
 Establishment of this Medicaid waiver drug program is contingent on approval of the 
waiver by the federal Health Care Financing Administration (HCFA). 
 
        The federal poverty levels for 1999 are: 
 
   100%  150%  185%  200% 
Family of one  $8240  $12,360 $15,244 $16,480 
Family of two  $11,060 $16,590 $20,461 $22,120 
 
 
 D.  Other prescription drug programs and proposals 
 
  1.  Federal Office of Drug Pricing.  The Office of Drug Pricing (ODP), part of 
the Bureau of Primary Health Care within the U.S. Department of Health and Human Services, is 
responsible for the implementation and management of Section 340B of the Public Health Service 
Act (enacted as part of the Veterans Health Care Act of 1992, PL 102-585).  Section 340B 
provides that a manufacturer who sells covered outpatient drugs to eligible entities must sign a 
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pharmaceutical pricing agreement with the Secretary of Health and Human Services in which the 
manufacturer agrees to charge a price for covered outpatient drugs that will not exceed an 
amount determined under a statutory formula.  Although the price calculation is the s me as the 
Medicaid rebate calculation, the purchasers under the 340B program pay the reduced cost 
upfront, rather than first paying full price and receiving a rebate later.  The costs of drugs under 
the 340B program are generally, but not always, slightly higher than the Federal Supply Schedule. 
 
 An entity is eligible to take advantage of the 340B program prices if it falls within the 
program’s definition of “covered entity.”  “Covered entities” are defined in the statute as follows. 
° Federally-qualified health centers 
° Entities receiving grants for health services for residents of public housing
° Qualified family planning projects 
° HIV early intervention programs 
° State-operated AIDS drug purchasing assistance programs 
° Qualified black lung clinics 
° Qualified comprehensive hemophilia diagnostic treatment centers 
° Qualified Native Hawaiian Health Centers 
° Qualified urban Indian organizations receiving funds under the Indian Health Care 
Improvement Act 
° Qualified HIV health care services programs 
° Entities receiving funds for treatment of sexually transmitted diseases or tuberculosis 
° Qualified “subsection (d) hospitals” 
 
 Certain restrictions apply to the covered entities and their practices in order to maintain 
eligibility under the ODP program.  The "Entity Guidelines" published in the Federal Register 
prohibit covered entities from reselling or otherwise transferring outpatient drugs purchased at the 
statutory discount to an individual who is not a patient of the covered entity.  The ODP definition 
of a patient (see F deral Register Notice, "Patient and Entity Eligibility", October 
24, 1996, p.55157, Item (C)) states:  "An individual is a "patient" of a covered entity (with the 
exception of State-operated or funded AIDS drug purchasing assistance programs) only if: (1) the 
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covered entity has established a relationship with the individual, such that the covered entity 
maintains records of the individual's health care: and (2) the individual receives health care 
services from a health care professional who is either employed by the covered entity or provides 
health care under contractual or other arrangements (e.g. referral for consultation) such that 
responsibility for the care provided remains for the covered entity; and (3) the individual receives 
a health care service or range of services from the covered entity which is consistent with the 
service or range of services for which grant funding or Federally-qualified health center look-alike 
status has been provided to the entity.  Disproportionate share hospitals are exempt from this 
requirement. An individual will not be considered a "patient" of the entity for purposes of 340B if 
the only health care service received by the individual from the covered entity is the dispensing of 
a drug or drugs for subsequent self-administration or administration in the home setting.  An 
individual registered in a State operated or funded AIDS drug purchasing assistance program 
receiving financial assistance under title XXVI of the PHS Act will be considered a "patient" of 
the covered entity for purposes of this definition if so registered as eligible for the State program." 
 
 Entities in Maine listed in the ODP’s database as participating the ODP programs are 
listed in Appendix E. 
 
 2.  Canadian pricing   Several studies have pointed out that prescription drug prices in 
Canada, as well as in other countries, are significantly lower than U.S. drug prices for the same 
medication14.  The Canadian health department -- H al h Canada -- regulates the price of patented 
drugs.  Once a new prescription drug is approved for market by the Therapeutics Products 
Program of the Health Protection Branch of Health Canada, the maximum price the manufacturer 
can charge is established by the Patented Medicine Prices Review Board15.  The mandate of the 
PMPRB is to ensure that the prices of patented medicines are not excessive.  If the PMPRB 
determines that a manufacturer has charged excessive prices, it can recover double the excess 
revenues from the manufacturer.  The PMPRB follows fairly extensive guidelines in stablishing
                                         
14 Congressional Research Service, Prescription Drug Price Comparisons: The United States, Canada and Mexico, 
David Cantor, January 23, 1998. 
 
15 Patented Medicine Prices Review Board, Health Canada, Compendium of Guidelines, Polices and Procedures, 
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prices and in determining whether excessive prices have been charged.  In general, prices paid to 
the manufacturer are tied to the prices of other drugs in the same therapeutic class and the range 
of prices paid in seven other countries:  France, Germany, Italy, Sweden, Switzerland, the United 
States and the United Kingdom.  Price increases are tied to the Consumer Price Index. 
 
 After the PMPRB establishes the maximum price, each Province negotiates with the 
manufacturer for the price it will pay for the drug.  As provincial plans cover about 44% of all 
prescription drug sales in Canada, each Province carries significant weight in the negotiations.  
Private insurers can also negotiate with the manufacturers for the best price under their plans, but 
in practice that price is the same as the price established for the provincial plans. 
 
 
3.  Other states’ approaches.  The Commission looked at how other states have 
approached the increasing lack of affordability of prescription drugs.  Nevada has enacted a 
program to pay up to $480 of prescription drug insurance premiums for seniors without such 
coverage.  New Hampshire has established a plan for seniors which is administered by a private 
entity and under which the private entity negotiates lower prices with manufacturers.  Missouri 
established a state annual income tax credit of up to $750 for pharmaceutical costs incurred by 
qualified seniors and disabled veterans.  California recently passed legislation directing pharmacies 
that participate in the California Medicaid program to also offer a discount to all Medicare 
beneficiaries16. 
                                                                                                                              
www.pmprb-cepmb.gc.ca/comp-in-e.html. 
16 National Conference of State Legislatures, “Making Medicines Affordable,” Richard Cauchi, State Legislatures, 
December 1999, pp. 10-11. 
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III Findings and Recommendations 
 
 A.  Findings.  The Commission makes the following findings. 
 
1.  Prescription medications are essential to the life and health of Maine 
residents, while remaining unaffordable to some, particularly the elderly. 
  
2.  About 25% of Maine residents are on their own when purchasing 
prescription medicines because they do not have private medication 
insurance, do not qualify for state or federal assistance programs, cannot 
afford to purchase drug coverage insurance, or, lastly, although they can 
afford them, choose not to purchase a drug insurance program.   
 
3.  Maine residents who have no prescription drug coverage pay the full 
retail price for prescription drugs.  Those who are covered by a prescription 
drug program benefit from the volume purchases of prescription medications 
made by their health insurance provider, the state Medicaid Program, the 
federal Office of Drug Pricing, private Pharmacy Benefit Managers or other 
private health care providers, and usually pay a co-pay on a negotiated 
discounted price.   
 
4.  Although large volume purchasers can often negotiate lower prescription 
drug costs, and competition at the retail level may result in savings to the 
consumer, there are many other factors which also affect the cost of 
prescription drugs. 
 
5.  The State has considerable clout in negotiating volume discounts, as 
indicated by the establishment both components of the ELCDP, the Maine 
Medicaid Program and General Assistance.  Without detailed investigation, 
the implementation of a separate distribution system appears very costly, 
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which may negate any savings that the State could achieve through bulk 
purchasing. 
 
6.  The 119th Maine Legislature approved the Maine Residents Low-Cost 
Drug Program, which is scheduled to begin in 2000, and significantly 
expanded the Elderly Low-Cost Drug Program. 
 
7.  Maine prescribers, pharmacists and other health care professionals want 
to help their patients acquire effective prescription medications at reasonable 
prices. 
 
8.  The affordability of prescription drugs is a national issue, not unique to 
Maine. 
 
 B.  Recommendations.  The following are unanimous recommendations of the 
Commission. 
 
1.  The Commission recommends that the State should not at this time  
pursue bulk purchasing of prescription drugs as a separate program.   
 
2.  The Commission recommends that the State expand educational outreach 
to inform Maine citizens about the many State, Federal and private 
programs available to reduce prescription costs.   
 
3.  The Commission recommends that the State investigate the possibility of 
joining with other states, especially in local or regional affiliations, to lower 
prescription drug costs to consumers. 
 
4.  Recognizing that the Legislature and the Department of Human Services 
anticipate that the Maine Residents Low-Cost Drug Program will reduce 
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prescription drug costs to consumers, the Commission recommends that the 
State move forward as rapidly as possible with the rule-making and 
legislative process to implement the program. 
 
5.  The Commission recommends that the availability of access to reduced-
cost prescription drugs through the federal Office of Drug Pricing be 
explored more thoroughly to determine whether prescription drugs at a 
lower price can be made more available to programs providing services to 
Maine residents.   
 
6.  The Commission recommends that the State encourage a public-private 
partnership to generate, maintain and distribute a simple and coordinated 
therapeutic and pricing guideline for physicians and other prescribers. 
 
7.  The Commission recommends that the State encourage public-private 
partnerships for expanded purchasing volume, thereby increasing ability to 
purchase prescription drugs at lower prices. 
 
8.  The Commission recommends that the Department of Human Services 
continue to pursue the Medicaid waiver with the Health Care Financing 
Administration. 
 
 
 
 
 
 
 
RESOLVES 
First Regular Session of the 119th 
 
 
 
CHAPTER 75 
 
H.P. 144 - L.D. 206 
 
Resolve, to Establish the Commission to Study Bulk Purchasing of Prescription Drugs and 
Medical Supplies 
 
Emergency preamble. Whereas, Acts and resolves of the Legislature do not become effective until 90 days 
after adjournment unless enacted as emergencies; and 
 
Whereas, a comprehensive study of bulk purchasing of prescription drugs and medical supplies is needed to 
determine whether bulk purchasing could be used to provide Maine residents access to affordable 
prescription drugs and medical supplies, such a study to be undertaken during the summer and fall of 1999; 
and 
 
Whereas, in the judgment of the Legislature, these facts create an emergency within the meaning of the 
Constitution of Maine and require the following legislation as immediately necessary for the preservation of 
the public peace, health and safety; now, therefore, be it 
 
 Sec. 1. Commission established. Resolved: That there is established the Commission to Study Bulk 
Purchasing of Prescription Drugs and Medical Supplies, referred to in this resolve as the "commission"; 
and be it further 
 
 Sec. 2. Membership. Resolved: That the commission consists of 12 members appointed as follows: 
 
 1. The President of the Senate shall appoint 5 members as follows: 
 
A. Two Senators, one from each major political party. The first-named Senator is the Senate chair;  
B. One person from a professional organization representing pharmaceutical manufacturers;  
C. One person from a statewide organization representing health care carriers regulated under the 
Maine Revised Statutes, Titles 24 and 24-A; and  
D. One person from a statewide organization representing hospitals; 
 
 2. The Speaker of the House of Representatives shall appoint 5 members as follows: 
 
A. Four Representatives, 2 from each major political party. The first-named Representative is the House      
chair; and  
     B. One person from a statewide organization representing pharmacies; and 
 
     3. The Governor shall appoint 2 members as follows:
 
     A. The Director of the Bureau of Medical Services within the Department of Human Services or the 
     director's designee; and  
     B. One person from a statewide organization representing pharmaceutical wholesalers; and be it further 
 
     Sec. 3. Appointments; meetings. Resolved: That all appointments must be made no later than 30 days 
following the effective date of this resolve. The appointing authorities shall notify the Executive Director of 
the 
Legislative Council upon making their appointments. When the appointment of all members is complete, 
the chairs 
shall call and convene the first meeting of the commission no later than July 30, 1999; and be it further 
 
     Sec. 4. Duties. Resolved: That the commission shall study bulk purchasing of prescription drugs and 
medical supplies. The commission shall study the need for a bulk purchasing mechanism and the financial 
benefits 
and potential savings to private citizens, insurance carriers, self-insu d employee health benefit plans and 
publicly 
funded health coverage. The commission shall evaluate the potential impact of bulk purchasing on the 
State's 
economy and on pharmacies, hospitals and other health care facilities within the State. In its report, the 
commission shall propose a plan for bulk purchasing that represents the best judgment of a majority of the
members of the commission for a bulk purchasing mechanism for the State. 
 
     In examining the issue of bulk purchasing of prescription drugs and medical supplies, the commission 
may 
examine bulk purchasing mechanisms in use in other states and countries and shall consult with interested 
parties 
representing a broad range of views. 
 
     The commission is authorized to meet as necessary to complete its work, up to a maximum of 4 
meetings of
the commission; and be it further 
 
     Sec. 5. Staff assistance. Resolved: That the commission may request staffing and clerical assistance 
from 
the Legislative Council; and be it further 
 
     Sec. 6. Compensation. Resolved: That the commission members who are Legislators are entitled to 
receive 
the legislative per diem, as defined in the Maine Revised Statutes, Title 3, section 2, for each day's 
attendance at 
meetings of the commission and are entitled to reimbursement for travel and other necessary expenses, 
upon 
application to the Legislative Council. The Executive Director of the Legislative Council shall administer 
the 
commission's budget; and be it further 
 
     Sec. 7. Report. Resolved: That the commission shall submit its report with any accompanying 
legislation to
the Joint Standing Committee on Health and Human Services by December 1, 1999. If the commission 
requires a 
limited extension of time to conclude its work and make its report, it may apply to the Legislative Council, 
which 
may grant the extension. Upon submission of its required reports, the work of the commission terminates; 
and be 
it further 
 
     Sec. 8. Appropriation. Resolved: That the following funds are appropriated from the General Fund to 
carry 
out the purposes of this resolve. 
 
          1999-00 
 
LEGISLATURE 
 
Commission to Study Bulk Purchasing of Prescription Drugs and Medical Supplies 
 
     Personal Services $1,320  
     All Other 1,700 
 
     Provides funds for the per diem and expenses of legislative members for 4 me tings o  the Commission 
to 
     Study Bulk Purchasing of Prescription Drugs and Medical Supplies and to print the required report. 
 
LEGISLATURE ____________  
TOTAL $3,020 
 
     Emergency clause. In view of the emergency cited in the preamble, this resolve takes effect when 
approved. 
 
                                  Effective June 17, 1999. 
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Commission to Study Bulk Purchasing of Prescription Drugs and Medical Supplies 
Resolve 1999, Chapter 75 
 
Appointments by the Governor 
 
· Robert E. Carroll, Jr., R.Ph. 
 Department of Professional and Financial Regulation 
  
· William Griffin 
 Bindley Western, Goold Division 
  
 
Appointments by the President of the Senate 
 
· Senator Peggy A Pendleton, R.N., Chair 
 Senate District 31 (Cumberland County) 
  
· Senator I. Joel Abromson 
 Senate District 27 (Cumberland County) 
  
· Bruce Daniels, R.Ph., MBA 
 MaineGeneral Medical Center 
 (representing a statewide organization representing hospitals) 
  
· David L. Massanari, M.D. 
 Harvard Pilgrim Health Care 
 (representing a statewide organization representing health care carriers) 
  
· Marjorie E. Powell, Esq. 
 Pharmaceutical Research and Manufacturers of America (PhRMA) 
 (representing a professional organization representing pharmaceutical manufacturers) 
  
  
Appointments by the Speaker of the House of Representatives 
 
· Representative Elaine Fuller, R.N., Chair 
 House District 80 (Manchester) 
  
· Representative Joseph Bruno, R.Ph. 
 House District 38 (Raymond) 
  
· Representative David G. Lemoine 
 House District 20 (Old Orchard Beach) 
  
· Representative Christine Savage 
 House District 60 (Union) 
  
· Reginald S. Gracie, Jr., R.Ph. 
 Rite-Aid Corporation; Maine Pharmacy Association 
 (representing a statewide organization representing pharmacies) 
 
Medicaid Outpatient Prescription Drug Spending
SFY 97 SFY 98 Chg SFY 99 Chg
Gross Expenditures $98,964,628 $109,697,688 10.8% $135,493,928 23.5%
Drug Rebates -$17,206,484 -$20,206,046 17.4% -$27,957,863 38.4%
Net Expenditures $81,758,144 $89,491,642 9.5% $107,536,065 20.2%
Drug Rebate Percentage 17.4% 18.4% 20.6%
Number of Drug Recipients 141,220 144,205 2.1% 148,654 3.1%
Gross Exp Per Recipient $700.78 $760.71 8.6% $911.47 19.8%
Net Exp Per Recipient $578.94 $620.59 7.2% $723.40 16.6%
Number of Prescriptions 2,793,666 2,870,422 2.7% 3,114,155 8.5%
Prescriptions per Recipient 19.8 19.9 0.6% 20.9 5.2%
Expenditures per Prescription $35.42 $38.22 7.9% $43.51 13.8%
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Federal Office of Drug Pricing 
 
 Entities in Maine listed in the Office of Drug Pricing’s database as participating the ODP 
programs include: 
° Bucksport Regional Health Center 
° Regional Medical Center at Lubec 
° Health Care for Portland’s Homeless Project 
° Tri-County Health Services, Farmington Family Planning Clinic 
° Rumford Family Planning Clinic 
° Machias Family Planning Clinic 
° Health 1st Family Planning Clinic (Fort Kent) 
° Midcoast Clinic (Belfast) 
° Skowhegan Family Planning Clinic, Michelle Boulette Center 
° Planned Parenthood of Northern New England (Portland)
° Planned Parenthood of Northern New England (Biddeford)) 
° Planned Parenthood of Northern New England (Brunswick)  
° Planned Parenthood of Northern New England (Sanford) 
° Portland Division of Public Health 
° Maine Department of Human Services, Bureau of Health, HIV/STD Program 
° Penquis health Services (Bangor) 
° Dexter Family Planning Clinic 
° Guilford Family Planning Clinic 
° Lincoln Family Planning Clinic 
° City of Portland, Public Health Division 
° Millinocket Family Planning Clinic 
° Milo Family Planning Clinic 
° Sacopee Valley Health Center, Family Planning Clinic 
° Auburn Family Planning Clinic 
° Norway Family Planning Clinic 
Appendix E  page 2 
° Calais Family Planning Clinic 
° Arthur Jewell Community Health Center, Reynolds Road Brooks) 
° Health 1st, Houlton Family Planning Clinic 
° Health 1st Family Planning (Madawaska) 
° Midcoast Family Planning Clinic (Damariscotta) 
° Midcoast Family Planning Clinic (Rockland) 
° Health 1st, Patten Family Planning  
° KVCAP Family Planning (Jackman) 
° Pittsfield Family Planning Clinic 
° KVCAP family Planning (Hinckley) 
° Health 1st Family Planning Program (Presque Isle) 
° Kennebec Family Planning (Augusta) 
° Downeast Health Services, Inc., Family Planning Clinic (Ellsworth)
° Kennebec Valley Community Action (Waterville) 
° Penquis Community Action Program (Bangor) 
° Western Maine Community Action (East Wilton) 
° Aroostook County Action Program (Presque Isle) 
° Penobscot Bay Medical Center  
° Family Planning Association of Maine, Inc. (Augusta) 
° Maine Department of Human Services 
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